• Dr. Silvia Navis
• Malavika Ashok
• Bency Bernard
• Archana J.R.
• Surabhi S.V.

ABSTRACT Aim: - A hospital based prospective observational study was done at a tertiary care hospital over a period of six months. The aim of our study was to assess which of the combination was efficacious when comparing Pantoprazole-Itopride with Pantoprazole-Domperidone. Diabetic Gastroparesis is outlined as a clinical condition that is characterised by upper Gastro Intestinal dyspeptic symptoms (nausea, bloating, vomiting, weight loss, postprandial fullness) in association with delayed gastric emptying leading to poor glycemic management, poor nutrition and dehydration. Usual management for Diabetic Gastroparesis includes Nutritional Assessment, Dietary modification, Glycaemic control, Prokinetic agents and Proton Pump Inhibitors. Materials and Methods: - In this study, two groups each comprised of 23 subjects (i.e., total of 46 subjects) where group I administered with Pantoprazole 40mg – Itopride 150mg (Pantop-IT capsules) and group II with Pantoprazole 40mg – Domperidone 30mg (Pantop-DO capsules). The quality of life of patient were assessed using Patient Assessment of Upper Gastro Intestinal disorders (PAGI-QoL). Gastroparesis Cardinal Symptom Index (GCSI) were used to analyze symptomatic betterment. Nutritional statuses of patients were analyzed using Mini Nutritional Assessment Scale (MNA). The questionnaire was given to the patients before and after the counselling. Side effect profile were monitored using General Assessment of Side Effects scale (GASE). Results: - Pantoprazole – Itopride therapy efficiently improve the symptoms such as abdominal pain, regurgitation, loss of appetite, flatulence, belching, dyspepsia and bloating than Pantoprazole-Domperidone (18.36 ± 16.77; 18.69 ± 17.52). It is seen that, there was a statistically significant difference (p <0.05) between Group I Pantoprazole – Itopride than Group II Pantoprazole-Domperidone. Conclusion: - It can be concluded that the symptomatic betterment was achieved greater in patients receiving Pantoprazole - Itopride therapy with minimum side effect profile and better tolerance when compared to Pantoprazole – Domperidone combination. Quality of life was improved in patients receiving Pantoprazole – Itopride. Nutritional deficiency assessed in our study population was also improved in patients receiving Pantoprazole – Itopride.

Diabetic Gastroparesis, Itopride, Domperidone, Hyperglycaemia, Medication Adherence

"A PROSPECTIVE OBSERVATIONAL STUDY ON THE EFFICACY AND SIDE EFFECTS OF PANTOPRAZOLE-DOMPERIDONE COMPARED WITH PANTOPRAZOLE-ITOPRIDE COMBINATION IN TYPE 2 DIABETIC GASTROPARESIS AND ASSESSMENT OF QUALITY OF LIFE OF PATIENTS BEFORE AND AFTER THERAPY IN A TERTIARY CARE HOSPITAL", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.8, Issue 7, page no.f78-f91, July-2021, Available :http://www.jetir.org/papers/JETIR2107641.pdf

"A PROSPECTIVE OBSERVATIONAL STUDY ON THE EFFICACY AND SIDE EFFECTS OF PANTOPRAZOLE-DOMPERIDONE COMPARED WITH PANTOPRAZOLE-ITOPRIDE COMBINATION IN TYPE 2 DIABETIC GASTROPARESIS AND ASSESSMENT OF QUALITY OF LIFE OF PATIENTS BEFORE AND AFTER THERAPY IN A TERTIARY CARE HOSPITAL", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.8, Issue 7, page no. ppf78-f91, July-2021, Available at : http://www.jetir.org/papers/JETIR2107641.pdf